Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced the promotion of Thomas Englese to chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will now lead the company's commercial strategy, overseeing sales, marketing, market access, and commercial operations for its key products, including TONMYA for fibromyalgia and the acute migraine treatments Zembrace SymTouch and Tosymra.
The promotion comes at a pivotal time for Tonix as it works to expand the launch of TONMYA, which was approved by the U.S. Food and Drug Administration and is the first new treatment for fibromyalgia in more than 15 years. Seth Lederman, president and chief executive officer of Tonix, said Englese has been 'instrumental in building Tonix's commercial organization and launching TONMYA,' highlighting his role in the company's progress. Englese expressed his commitment to 'expanding access, growing our patient and prescriber base, and increasing sales' as the company broadens the TONMYA launch.
Englese's promotion to chief commercial officer underscores Tonix's dedication to maximizing the commercial potential of its CNS portfolio. The company's focus on fibromyalgia and acute migraine addresses significant unmet medical needs, and the commercial team is expected to play a crucial role in driving adoption of TONMYA among health care providers and patients. With fibromyalgia affecting millions of Americans, the successful commercialization of TONMYA could offer a new therapeutic option for those who have had limited choices for managing their condition.
In addition to its marketed products, Tonix is advancing a pipeline that includes TNX-2900 for Prader-Willi syndrome, a rare disease, and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for prevention of kidney transplant rejection. The company's commitment to CNS and immunology research highlights its strategic focus on areas with high unmet need. For more information on the full press release, visit https://ibn.fm/uzRyl.
Investors and stakeholders can keep up with the latest news and updates from Tonix Pharmaceuticals at the company's newsroom: https://ibn.fm/TNXP.
